GLP-1 receptor agonists were first developed in the early 2000s Weight loss was initially observed as a secondary effect, not the primary goal For nearly two decades, these medications were studied primarily through the lens of blood sugar regulation and insulin sensitivity
Some microbes transform toxic mycotoxins into less harmful metabolites, while others bind toxins to their cell walls, reducing their absorption
Early discontinuation may be overestimated if treatment occurred outside the purview of the claims data source 13 KESIMPTA received approval in August 2020, resulting in a relatively limited number of patients with sufficient real-world follow-up data to assess persistence and adherence
Current UK Guidance on GLP-1 Use During Lactation Current evidence regarding GLP-1 receptor agonist safety during breastfeeding is extremely limited , and UK regulatory guidance is clear: these medications should not be used during breastfeeding
Many patients report that they feel cleaner or more vibrant when they prioritize antioxidant support alongside their weight loss medication
C., & Hovda, D
